Tag: SCLC
-
Immunotherapy Advances in SCLC: Promise, Limits, and the Biomarker Challenge
Current gains from immunotherapy in small cell lung cancer (SCLC) Immunotherapy has altered the treatment landscape for SCLC, offering meaningful efficacy where options were once limited. Checkpoint inhibitors that unleash the body’s immune system to attack cancer cells have demonstrated survival benefits in certain patients and disease settings, particularly when used in first-line combinations or…
-
Immunotherapy Advances in SCLC: Promise, Limitations, and the Biomarker Gap
Immunotherapy Advances in Small Cell Lung Cancer (SCLC): A Quiet but Persistent Shift Small cell lung cancer has long challenged clinicians with its aggressive biology and historically limited treatment options. In recent years, immunotherapy has emerged as a meaningful, if nuanced, addition to the standard of care. The story is not a single triumph but…
-
Immunotherapy Advances in SCLC: Promise, Limitations, and Biomarker Needs
Overview: Immunotherapy’s Emerging Role in SCLC Small cell lung cancer (SCLC) has long challenged clinicians with its aggressive biology and tendency for rapid relapse. In recent years, immunotherapy has emerged as a beacon of hope, offering meaningful efficacy gains in several lines of treatment. This article reviews the current state of immunotherapy in SCLC, highlighting…
-
ABBV-706: A Promising Treatment for Relapsed/Refractory SCLC
Introduction to ABBV-706 and Its Significance Small cell lung cancer (SCLC) is a particularly aggressive form of lung cancer characterized by rapid growth and early metastasis. Treatment options for patients with relapsed or refractory SCLC have historically been limited. However, recent advancements, particularly the emergence of novel therapies like ABBV-706, have provided new hope. This…
-
Durable Responses with ABBV-706 in Relapsed/Refractory SCLC
Introduction to ABBV-706 Small cell lung cancer (SCLC) is known for its aggressive nature and poor prognosis, especially in patients who have experienced relapse. Recent advancements in targeted therapies are paving the way for better outcomes. ABBV-706, an antibody-drug conjugate (ADC) that targets the seizure-related homolog protein 6 (SEZ6), has emerged as a potential game-changer.…